Immucell (ICCC) Gross Profit (2010 - 2026)

Immucell (ICCC) has reported Gross Profit for 17 consecutive years, with $2.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Profit fell 13.51% year-over-year to $2.4 million; the trailing twelve-month figure through Jun 2026 stood at $10.5 million (down 0.55% YoY), and the FY2025 full-year result was $11.4 million, up 44.13% from the prior year.
• Gross Profit eased to $2.4 million in Q2 2026 per ICCC's latest filing, from $2.9 million in the prior quarter.
• Across five years, Gross Profit topped out at $3.4 million in Q1 2025 and bottomed at $300775.0 in Q1 2023.
• Historically, Gross Profit has averaged $2.0 million across 5 years, with a median of $2.1 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Gross Profit plunged 90.31% in 2023, then surged 663.15% in 2024.
• Over 5 years, Gross Profit stood at $992176.0 in 2022, then advanced by 27.69% to $1.3 million in 2023, then soared by 123.51% to $2.8 million in 2024, then rose by 2.77% to $2.9 million in 2025, then retreated by 16.25% to $2.4 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $2.4 million, $2.9 million, and $2.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.